吉非替尼联合立体定向治疗Ⅲ期非小细胞肺癌疗效观察  

Efficacy and safety of gefitinib combined with stereotactic radiotherapy for patients with NSCLC of stage Ⅲ

作　　者：姜学东[1] 王亚辉[1] 宇萌[2] 赵岩[2] 王琼[1] 

机构地区：[1]武警辽宁总队医院胸外科,辽宁沈阳110034 [2]武警辽宁总队医院放疗科,辽宁沈阳110034

出　　处：《武警后勤学院学报（医学版）》2014年第4期293-295,共3页Journal of Logistics University of PAP（Medical Sciences）

摘　　要：【目的】评价吉非替尼联合立体定向放射治疗对Ⅲ期非小细胞肺癌的疗效。【方法】我科89例患者经病理证实均为腺癌，随机分为2组，治疗组47例，对照组42例。治疗组采用SGS—I型超级伽马刀治疗，单次剂量3．0～3．6Gy，1次／d，5次／周，总治疗次数为10-14次，总剂量50～55Gv。立体定向放疗同时口服吉非替尼，250mg／d。并维持至疾病进展或其他原因停药为止，对照组仅行超级伽玛刀治疗，单次剂量3．0～3．6Gy，1次／d，5次／周，总治疗次数13-16次，总剂量60～65Gy。【结果】治疗后3个月复查，治疗组近期有效率为78．7％。中位生存期为203个月，1年生存率为76．2％，2年生存率为45．3％。对照组近期有效率为61．9％，中位生存期为10．5个月，1年生存率为52．6％，2年生存率为32．1％。以上两组结果有统计学意义（P〈0．05）。【结论】吉非替尼联合赢体定向放疗对于中晚期非小细胞肺癌有较好的疗效且无特殊不良反应。[Objective]To evaluate the efficacy of gefitinib combined with stereotactic radiotherapy （SRT）for patients with non-small cell hmg cancer （NSCLC） of stage Ⅲ. [Methods] 47 patients were treated with gefitinib combined with stereotactic radiotherapy, while another 42 adenocarcinoma patients underwent gamma knife treatment. The treatment group adopted SGS- type super gamma knife treatment, a single dose was 3.0-3.6Gy, （1/d, 5 times per week）, the total number of treatment was 10~14 times, and the total dose was 50-55Gy. Stereotactic radiotherapy was combined with oral gefitinib （250 mg/d）, and oral gefitinib was maintained with the progression of the disease or to other causes of drug withdrawal. The control group was treated with super gammaknife, a single dose was 3.0- 3.6Gy （1/d, 5 times per week）, the total number of treatment was 13~ 16 times, and the total dose was 60-65Gy. [ Results] After treatment for 3 months, the effective rate was 78.7% in treatment group. The median survival time was 20.3 months, I year survival rate was 76.2%, and 2 year survival rate was 45.3%. The effective rate of the control group was 61.9%, the median survival period was 10.5 months, 1 year survival rate was 52.6%, and 2 year survival rate was 32.1%. There was statistical significance between the results of the above two groups （P 〈 0.05）. [ Conclusion ] Gefitinib combined with stereotactic radiotherapy for advanced NSCLC has better effect and no special adverse reaction.

关 键 词：吉非替尼 立体定向放疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]